Executive briefing: Piecing the puzzle together – reimbursement in the EU
This article was originally published in Clinica
Executive Summary
Getting a medical device reimbursed is critical for its market adoption. In Europe, the complex and highly fragmented reimbursement landscape presents itself as a major challenge to medtech companies of all sizes. In this report, IBI analyst Phil Greenfield offers a guide to piecing together the reimbursement puzzle and an overview of reimbursement in the five major EU markets
You may also be interested in...
Report Digest: Discussing What's Going On With Prostate Cancer Diagnosis And Treatment
In this edition of Report Digest, UK-based reporter Barnaby Pickering talks about the prostate cancer diagnostics and minimally invasive treatments markets with analyst Phil Greenfield. The two discuss ongoing developments in both treatment and diagnosis, while exploring driving and limiting factors for both.
Using Digital Tools To Unpick The Adherence Problem
An ambitious five-year public-private partnership plans to tackle non-adherence to medicines by giving patients EU-wide access to regulator-approved digital drug information. One year in, progress has been made in creating an app that could do just this.
In A First, FDA Approves Radioembolization Treatment For Liver Cancer In US
Approval for Boston Scientific’s TheraSphere offers further access to the therapy that, until now, has only been available under a humanitarian device exemption.